<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02392689</url>
  </required_header>
  <id_info>
    <org_study_id>IMPACT-EU</org_study_id>
    <nct_id>NCT02392689</nct_id>
  </id_info>
  <brief_title>Improve Management of Heart Failure With Procalcitonin</brief_title>
  <acronym>IMPACT-EU</acronym>
  <official_title>Improve Management of Heart Failure With Procalcitonin - Biomarkers in Cardiology 18</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brahms AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brahms AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients presenting to the Emergency Department with shortness of breath and (suspected)
      heart failure will be screened and randomized to either a standard of care or a
      procalcitonin-guided arm.

      Procalcitonin-guided arm: a procalcitonin level (cutoff 0.2 ng/ml) will be used to support
      decision on antibiotic therapy initiation.

      Standard of care arm: the decision on antibiotic therapy will be based on the physicians
      intent to treat.

      The patients will be followed up 30 and 90 days after randomization to evaluate the survival
      status, re-hospitalizations and further antibiotic therapies.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause hospital readmission</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with diagnosis of pneumonia during index hospitalization</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">759</enrollment>
  <condition>Heart Failure</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>PCT-guided</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood samples are taken on day 0 and day 1 of the study. Procalcitonin (PCT) is measured and used support the decision on antibiotic therapy.
PCT levels above 0.2 ng/ml: antibiotic therapy is recommended PCT levels equal/below 0.2 ng/ml: antibiotic therapy is not recommended</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Blood samples are taken on day 0 and day 1 and stored for later analysis. The investigator treats the patients according to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Procalcitonin</intervention_name>
    <description>Procalcitonin guided antibiotic therapy</description>
    <arm_group_label>PCT-guided</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who present to the emergency department (ED) with leading symptom dyspnea

          2. Suspected or known heart failure

          3. midregional pro atrial natriuretic peptide (MR-proANP)&gt;300 pmol/L, brain natriuretic
             peptid (BNP) &gt;350 ng/ml or N-terminal of the prohormone brain natriuretic peptide
             (NT-proBNP)&gt;1800 ng/l

          4. Patient has given written Informed Consent within study timelines to allow antibiotic
             therapy within 8 hours

          5. Adult patients (i.e. &gt;18 years of age)

          6. Hospitalization for at least 1 overnight stay planned

        Exclusion Criteria:

          1. Patient participates in any other interventional clinical trial

          2. Trauma related shortness of breath

          3. Patient diagnosed with lung or thyroid cancer

          4. Known terminal disease with life expectancy of less than 6 months, e.g. advanced
             metastasized cancer disease

          5. Organ transplant requiring immunosuppression

          6. Abdominal, vascular or thorax surgery within the last 30 days

          7. End stage/advanced heart failure - defined by planned heart transplantation, or
             cardiogenic shock

          8. Female patients who have given birth within 3 months before study enrolment

          9. Current use of antibiotics or requirement of immediate antibiotic therapy before
             randomization and measurement of Procalcitonin

         10. End stage renal failure requiring dialysis

         11. Patient is not willing, or it is not possible or advisable for the patient, to follow
             the study schedule, including antibiotic therapy and 90 days follow up

         12. Patient has already participated in the clinical trial previously

         13. Pregnant or lactating women

         14. Patients who are institutionalized by official or judicial order

         15. Dependants of the sponsor, the contract research organization (CRO), the study site or
             the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Maisel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California-San Diego/VA San Diego Healthcare System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Möckel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>university hospital Charitè Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aalborg Sygehus</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitätsmedizin Berlin - CCM</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitätmedizin Berlin - CVK</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt Höchst GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik Heidelberg - Medizinische Klinik III</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Lübeck</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht UMC+</name>
      <address>
        <city>Maastricht</city>
        <zip>6229</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2015</study_first_submitted>
  <study_first_submitted_qc>March 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>February 14, 2018</last_update_submitted>
  <last_update_submitted_qc>February 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>procalcitonin</keyword>
  <keyword>biomarker</keyword>
  <keyword>antibiotic therapy</keyword>
  <keyword>emergency department</keyword>
  <keyword>cardiology</keyword>
  <keyword>in vitro diagnostics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

